AR105378A1 - METHODS OF TREATMENT OF DISORDERS OF DEVELOPMENT WITH GABOXADOL - Google Patents
METHODS OF TREATMENT OF DISORDERS OF DEVELOPMENT WITH GABOXADOLInfo
- Publication number
- AR105378A1 AR105378A1 ARP160102163A ARP160102163A AR105378A1 AR 105378 A1 AR105378 A1 AR 105378A1 AR P160102163 A ARP160102163 A AR P160102163A AR P160102163 A ARP160102163 A AR P160102163A AR 105378 A1 AR105378 A1 AR 105378A1
- Authority
- AR
- Argentina
- Prior art keywords
- syndrome
- gaboxadol
- disorders
- methods
- developmental
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos de tratamiento de trastornos del desarrollo, como por ejemplo el síndrome de Angelman, síndrome del X frágil, síndrome de temblor/ataxia asociado a X frágil (FXTAS), trastornos del espectro autista, autismo, síndrome de Asperger, trastornos generalizados del desarrollo, trastorno desintegrativo de la infancia, síndrome de Rett, síndrome de Lanau-Kleffner, síndrome de Prader-Willi, disquinesia tardía y/o síndrome de Williams, con gaboxadol o una sal farmacéuticamente aceptable del mismo. Los métodos proveen composiciones terapéuticas que se pueden utilizar para mejorar uno o más síntomas del trastorno del desarrollo. Reivindicación 1: Un método para tratar un trastorno del desarrollo, caracterizado porque comprende administrarle al paciente que lo necesita entre aproximadamente 0,05 mg y aproximadamente 30 mg de gaboxadol o de una sal farmacéuticamente aceptable de éste, de manera tal de obtener una mejora en el paciente durante más de 6 horas después de la administración.Methods of treating developmental disorders, such as Angelman syndrome, fragile X syndrome, fragile X-associated tremor / ataxia syndrome (FXTAS), autism spectrum disorders, autism, Asperger syndrome, generalized developmental disorders, Disintegrative disorder of childhood, Rett syndrome, Lanau-Kleffner syndrome, Prader-Willi syndrome, tardive dyskinesia and / or Williams syndrome, with gaboxadol or a pharmaceutically acceptable salt thereof. The methods provide therapeutic compositions that can be used to improve one or more symptoms of developmental disorder. Claim 1: A method for treating a developmental disorder, characterized in that it is administered to the patient in need between about 0.05 mg and about 30 mg of gaboxadol or a pharmaceutically acceptable salt thereof, so as to obtain an improvement in the patient for more than 6 hours after administration.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193717P | 2015-07-17 | 2015-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105378A1 true AR105378A1 (en) | 2017-09-27 |
Family
ID=59981619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102163A AR105378A1 (en) | 2015-07-17 | 2016-07-15 | METHODS OF TREATMENT OF DISORDERS OF DEVELOPMENT WITH GABOXADOL |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR105378A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| US11597726B2 (en) | 2020-05-20 | 2023-03-07 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
-
2016
- 2016-07-15 AR ARP160102163A patent/AR105378A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| US11597726B2 (en) | 2020-05-20 | 2023-03-07 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003542A1 (en) | Treatment methods for cystic fibrosis. | |
| MX2022004734A (en) | Methods of treating developmental disorders with gaboxadol. | |
| CL2021001292A1 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| CU20150163A7 (en) | DERIVATIVES OF 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO (3,4-c) PIRAZOL-6-ONA ACTIVE AS BET INHIBITORS | |
| AR107871A1 (en) | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | |
| AU2016219611A1 (en) | Compositions comprising mixtures of semifluorinated alkanes | |
| CU20170154A7 (en) | DERIVATIVES OF PIRAZOL-3-IL-AMINA SUBSTITUTED AS CDK INHIBITORS | |
| CR20140086A (en) | COMBINATION TREATMENTS FOR HEPATITIS C | |
| CR20160528A (en) | COMPOUNDS AND COMPOSITIONS TO INDUCE CONDROGENESIS | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| CL2021000030A1 (en) | Use of sgc stimulators for the treatment of mitochondrial disorders | |
| GT201600131A (en) | DERIVATIVES OF [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE AS PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITARY DISEASES SUCH AS LEISHMANIASIS | |
| PE20170469A1 (en) | METHODS TO IMPROVE MYOCARDIAL PERFORMANCE IN PATIENTS WITH PHONTANE SURGERY USING UDENAFILO COMPOSITIONS | |
| BR112016015190A2 (en) | PHARMACEUTICAL COMPOSITION NOT CONTAINING ANTIOXIDANT AND METHOD OF PREPARING THE SAME | |
| AR105378A1 (en) | METHODS OF TREATMENT OF DISORDERS OF DEVELOPMENT WITH GABOXADOL | |
| CL2020003143A1 (en) | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for the treatment of a parasitic disease | |
| MX362905B (en) | Combination treatment. | |
| PE20190321A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| CL2016002870A1 (en) | Bicyclic derivatives and pharmaceutical composition that includes them | |
| AR097590A1 (en) | METHODS TO TREAT THE FRAGILE X SYNDROME AND RELATED DISORDERS | |
| AR108792A1 (en) | COMPOSITIONS THAT INCLUDE TIMOLOL | |
| ECSP19048402A (en) | ASCORBIC ACID AND QUINONE COMPOUNDS FOR THE TREATMENT OF CHAGAS DISEASE | |
| UY33806A (en) | NOVEDOUS IMIDAZOQUINOLINE COMPOUNDS, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY TLR7? | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN | |
| AR090580A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |